Transport Pharma Inks License Deal With GlaxoSmithKline

Transport Pharmaceuticals will license its oral herpes treatment under development to GlaxoSmithKline, the company said. Financial details of the deal weren't disclosed, but Transport, a Framingham drug developer, said that its agreement with the British pharmaceutical giant gives it an up-front license fee from GlaxoSmithKline plus milestone and royalty payments. The deal will also include technical support for the treatment's upcoming late-stage human clinical trials in Europe.

Boston Business Journal (http://www.bizjournals.com/boston/stories/2005/01/24/daily39.html)